Sibaji Sarkar

Summary

Affiliation: Boston University
Country: USA

Publications

  1. ncbi request reprint Genetic and epigenetic aspects of breast cancer progression and therapy
    Shannon Byler
    Cancer Center, L913, Department of Medicine, Boston University School of Medicine, 72 E Concord St, Boston, MA 02118, U S A
    Anticancer Res 34:1071-7. 2014
  2. pmc Cancer development, progression, and therapy: an epigenetic overview
    Sibaji Sarkar
    Cancer Center, L913, Department of Medicine, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA
    Int J Mol Sci 14:21087-113. 2013
  3. doi request reprint Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy
    Sibaji Sarkar
    Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA
    Epigenomics 5:87-94. 2013
  4. ncbi request reprint Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor
    Megan A Mataga
    Cancer Center, Boston University School of Medicine, 72 East Concord Street, L 913, Boston, MA 02118, USA
    Anticancer Res 32:2523-9. 2012
  5. ncbi request reprint MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression
    Kripa Patel
    Cancer Center, Boston University School of Medicine, Boston, MA, United States
    Cancer Lett 347:54-64. 2014
  6. pmc Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells
    Andrew M Rankin
    Cancer Center and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
    Nucleic Acid Ther 23:311-21. 2013

Collaborators

  • Shannon Byler
  • Kripa Patel
  • Douglas V Faller
  • Sarah Heerboth
  • Andrew M Rankin
  • Genevieve Housman
  • Megan A Mataga
  • Sajal K Ghosh
  • Asami Takashima
  • Sarah Goldgar
  • Meghan Leary
  • Anita Kollory
  • Kimberly Moulton
  • Lora Forman
  • Shoshana Rosenthal
  • McKenna Longacre
  • Leah R Evans
  • Shannon Kokolus
  • Amrita Devalapalli

Detail Information

Publications6

  1. ncbi request reprint Genetic and epigenetic aspects of breast cancer progression and therapy
    Shannon Byler
    Cancer Center, L913, Department of Medicine, Boston University School of Medicine, 72 E Concord St, Boston, MA 02118, U S A
    Anticancer Res 34:1071-7. 2014
    ..Overall, breast cancer subtypes may have a similar epigenetic signal that promotes cancer development, and treatment may be most effective if both epigenetic and genetic differences are targeted. ..
  2. pmc Cancer development, progression, and therapy: an epigenetic overview
    Sibaji Sarkar
    Cancer Center, L913, Department of Medicine, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA
    Int J Mol Sci 14:21087-113. 2013
    ..Adopting epigenetic alteration as a new hallmark of cancer is a logical and necessary step that will further encourage the development of novel epigenetic biomarkers and therapeutics. ..
  3. doi request reprint Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy
    Sibaji Sarkar
    Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA
    Epigenomics 5:87-94. 2013
    ..In particular, we will consider how a combination therapy that includes epigenetic drugs could possibly kill cancer progenitor cells and reduce the chance of relapse following chemotherapy...
  4. ncbi request reprint Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor
    Megan A Mataga
    Cancer Center, Boston University School of Medicine, 72 East Concord Street, L 913, Boston, MA 02118, USA
    Anticancer Res 32:2523-9. 2012
    ....
  5. ncbi request reprint MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression
    Kripa Patel
    Cancer Center, Boston University School of Medicine, Boston, MA, United States
    Cancer Lett 347:54-64. 2014
    ..Our study thus identified a mechanism by which STAT3 signaling can be inhibited in pancreatic cancer cells by modifying let-7 expression. ..
  6. pmc Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells
    Andrew M Rankin
    Cancer Center and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
    Nucleic Acid Ther 23:311-21. 2013
    ....